Skip to main
TARA
TARA logo

TARA Stock Forecast & Price Target

TARA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protara Therapeutics Inc. demonstrates a favorable outlook due to the promising efficacy signals of its lead program, TARA-002, which achieved a 100% high-grade complete response rate in BCG-unresponsive patients and maintained a notable durability rate of 67% at 12 months. Additionally, the program showed a high-grade complete response rate of 76% among BCG-naïve patients, suggesting significant potential for market adoption across both academic centers and community practices that prioritize long-term outcomes. The overall positive feedback from key opinion leaders (KOLs) indicates that TARA-002 could become a competitive treatment option in the evolving landscape of therapies for patients with limited treatment alternatives.

Bears say

Protara Therapeutics faces a challenging outlook as management anticipates a decline in the clinical response (CR) rates for its therapies, which could impact the company's market position despite highlighting the substantial unmet needs in the treatment landscape for lymphatic malformations. The expectation of reduced real-world CR rates, particularly in the BCG-unresponsive setting, raises concerns about the overall effectiveness and market adoption of TARA-002 and other therapies in its portfolio. Additionally, uncertainties surrounding the company's valuation and the risks associated with achieving positive outcomes further contribute to the negative sentiment regarding its stock performance.

TARA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protara Therapeutics Inc (TARA) Forecast

Analysts have given TARA a Strong Buy based on their latest research and market trends.

According to 5 analysts, TARA has a Strong Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protara Therapeutics Inc (TARA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.